|
|
|
| Pathogenesis of idiopathic pulmonary fibrosis and progress in drug treatment#br# |
| FENG Xinli1 ZHUANG Pan1 LIU Junquan1,2▲ |
1.Department of Technology, Zhejiang Weiwei Biomedical Science and Technology Co., Ltd, Zhejiang Province, Hangzhou 310053, China;
2.Department of Technology, Hangzhou Golden Domain Medical Laboratory Co., Ltd, Zhejiang Province, Hangzhou 310053, China |
|
|
|
Abstract Idiopathic pulmonary fibrosis is an interstitial lung disease that can cause progressive damage to lung function. Studies have found that the cause of idiopathic pulmonary fibrosis is that the appearance of fibroblast foci leads to a large amount of extracellular matrix deposition, collagen accumulation, lung matrix destruction, alveolar structure damage, and alveolar epithelial cells cannot perform normal repair. Eventually lead to the damage of normal lung tissue structure and so on. Clinically, mesenchymal stem cells and their secreted exosomes or cytokines have a certain effect on the pathogenesis of idiopathic pulmonary fibrosis, and can reduce inflammation, reducing oxidative stress, and regulate extracellular matrix. This review summarizes the pathogenesis of idiopathic pulmonary fibrosis and the research progress of its drug therapy.
|
|
|
|
|
|
[1] Divya T，Dineshbabu V，Soumyakrishnan S，et al. Celastrol enhances Nrf2 mediated antioxidant enzymes and exhibits anti-fibrotic effect through regulation of collagen production against bleomycin-induced pulmonary fibrosis [J]. Chem Biol Interact，2016，246：52-62.
[2] Salton F，Volpe MC，Confalonieri M. Epithelial-Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis [J]. Medicina（Kaunas），2019，55（4）：83.
[3] Liu YM，Nepali K，Liou JP. Idiopathic Pulmonary Fibrosis：Current Status，Recent Progress，and Emerging Targets [J]. J Med Chem，2017，60（2）：527-553.
[4] Somogyi V，Chaudhuri N，Torrisi SE，et al. The therapy of idiopathic pulmonary fibrosis：what is next? [J]. Eur Respir Rev，2019，28（153）：190021.
[5] Mathai SK，Schwartz DA. Translational research in pulmonary fibrosis [J]. Transl Res，2019，209：1-13.
[6] Richeldi L，Collard HR，Jones MG. Idiopathic pulmonary fibrosis [J]. Lancet，2017，389（10082）：1941-1952.
[7] Lederer DJ，Martinez FJ. Idiopathic Pulmonary Fibrosis [J]. N Engl J Med，2018，378（19）：1811-1823.
[8] Li Y，Shang Q，Li P，et al. BMP9 attenuates occurrence of venous malformation by maintaining endothelial quiescence and strengthening vessel walls via SMAD1/5/ID1/α-SMA pathway [J]. J Mol Cell Cardiol，2020，147：92-107.
[9] Xiang J，Cheng S，Feng TL，et al. Neotuberostemonine attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages [J]. Int Immunopharmacol，2016，36：158-164.
[10] Downs CA，Johnson NM，Tsaprailis G，et al. RAGE-induced changes in the proteome of alveolar epithelial cells [J]. J Proteomics，2018，177：11-20.
[11] Elsherbiny NM，Said E，Atef H，et al. Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats：Effect on IL-33/ST2 signaling，oxidative stress and fibrosis suppression [J]. Chem Biol Interact，2020，315：108897.
[12] 钟长军，李琳，李俊，等.氧化应激在特发性肺纤维化中的作用及其机制研究进展[J].中国药理学通报，2012， 28（2）：169-172.
[13] Ghorbanzadeh AM，Hamed MA. Density functional theory based molecular dynamics study on hydrogen storage capacity of C24，B12N12，Al12N12，Be12O12，Mg12O12，and Zn12O12 nanocages [J]. Int J Hydrogen Energy，2020，45（11）：6745-6756.
[14] Cuellar MC，Straathof AJ. Downstream of the bioreactor：advancements in recovering fuels and commodity chemicals [J]. Curr Opin Biotechnol，2020，62：189-195.
[15] Zurkova M，Kriegova E，Kolek V，et al. Effect of pirfenidone on lung function decline and survival：5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry [J]. Respir Res，2019，20（1）：16.
[16] Richeldi L，Costabel U，Selman M，et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis [J]. N Engl J Med，2011，365（12）：1079-1087.
[17] Raghu G，Rochwerg B，Zhang Y，et al. An official ATS/ERS/JRS/ALAT clinical practice guideline：treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline [J]. Am J Respir Crit Care Med，2015，192（2）：644.
[18] 潘怡，王振兴，郭静，等.补阳还五汤对肺纤维化小鼠中介导细胞自噬的mTOR蛋白的调控机制探讨[J].中国实验方剂学杂志，2019，25（6）：23-31.
[19] 李壮花，董瑞.特发性肺纤维化中医药研究进展[J].国际中医中药杂志，2017，39（7）：658-661.
[20] 杨军.黄芪对博来霉素肺纤维化大鼠肺组织SOD、MDA含量表达的影响[J].云南中医中药杂志，2019，40（8）：67-69.
[21] 杨礼腾，刘欣，程德云，等.虫草菌粉调控肺纤维化大鼠肺胶原代谢失衡的作用及其机制[J].时珍国医国药，2012， 23（5）：1297-1299.
[22] 岳会敏，刘飞，李范林，等.冬虫夏草菌丝体提取物通过抑制炎性因子及Treg细胞功能缓解肺纤维化[J].中国免疫学杂志，2016，32（10）：1472-1476.
[23] Glassberg MK，Minkiewicz J，Toonkel RL，et al. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery（AETHER）：A Phase Ⅰ Safety Clinical Trial [J]. Chest，2017，151（5）：971-981.
[24] Li XH，Yue SJ，Luo ZQ. Mesenchymal stem cells in idiopathic pulmonary fibrosis Oncotarget [J]. Oncotarget，2017，8（60）：102600-102616.
[25] Zhang C，Yin X，Zhang J，et al. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis：a case report [J]. Exp Ther Med，2017，13（5）：1922-1926.
[26] Cargnoni A，Romele P，Bonassi Signoroni P，et al. Amniotic MSCs reduce pulmonary fibrosis by hampering lung B-cell recruitment，retention，and maturation [J]. Stem Cells Transl Med，2020，9（9）：1023-1035.
[27] Parimon T，Yao CF，Stripp BR，et al. Alveolar epithelial type Ⅱ cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis [J]. Int J Mol Sci，2020，21（7）：2269.
[28] Surh YJ，Chung HT，Na HK，et al. Progress in heme oxygenase research [J]. Arch Biochem Biophys，2020，685：108321.
[29] Antebi B，Mohammadipoor A，Batchinsky AI，et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome [J]. J Trauma Acute Care Surg，2018，84（1）：183-191.
[30] Wu X， Dao Thi VL，Huang Y，et al. Intrinsic immunity shapes viral resistance of stem cells [J]. Cell，2018，172（3）：423-438.e25. |
|
|
|
